Evidence map›Paper›PMID 41136843›Full record

ReviewAdvances in experimental medicine and biology2025

MSC Manufacture.

Chiara Giacomini, Francesco Dazzi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chiara GiacominiSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK. chiara.giacomini@kcl.ac.uk.
Francesco DazziSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cell (MSC) therapy holds promising potential for the treatment of various pathological conditions associated with inflammatory processes. Despite encouraging outcomes in preclinical studies, the transition to successful clinical trials has been hindered by the absence of patient stratification criteria, the limited understanding of the in vivo mechanism of action, and the variability in MSC preparations. In this chapter, we address the major challenges in establishing a standardized manufacturing platform for MSC products and suggest new approaches to advance their clinical success.

Indexed as

Cell Culture TechniquesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsHumansCell therapyManufacturingMesenchymal stromal cellsPotency assayRelease criteria

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.